Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation : = Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation

The current situation of Sars-Cov-2 pandemic generates fears in the general population. Among patients receiving long-term immunomodulatory drugs, especially in the context of auto-immune diseases, there may be legitimates interrogations about the appropriateness of continuing treatment, without modification, in the current context. Most patients with Juvenile Rheumatoid Arthritis benefit from long-term immunmodulatory therapy (DMARD - disease modifying anti-rheumatic drug), more or less combined with regular use of non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids.The present study will characterize this issue by defining the proportion of patients whose usual treatment of Rheumatoid Arthritis has been modified in relation to the actual sanitary crisis.

Year of Publication: 2020
Published: Bethesda (Maryland), ClinicalTrials.gov, May 29, 2020
Language: English
Full text access: Full text access (free access)
Links: Full Text (clinicaltrials.gov)
Keywords: Arthritis, Rheumatoid > MeSH
Arthritis > MeSH
COVID
Clinical Study Status: Recruiting
Clinical Study
Forschungsbericht
Klinische Studie
Observational Study
Rheumatoid Arthritis
Notes: Source: ClinicalTrials.gov (no modifications made)
ClinicalTrials.gov processed this data on June 05, 2020
Last update posted on ClinicalTrials.gov: May 29, 2020
Last updated: 2020-06-08
NCT ID:
    NCT04393233

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 02661nam a22005052 4500
001 CTG003395979
003 DE-627
005 20200609024455.0
007 cr uuu---uuuuu
008 200609s2020 xx |||||ot 00| ||eng c
028 5 2 |a CTg_2020-06-08.pp 
035 |a (DE-627)CTG003395979 
035 |a (DE-599)NCTNCT04393233 
035 |a (NCT)RHUMACOVID ( 29BRC20.0110) 
035 |a (NCT)NCT04393233 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
084 |a PHARMAZIE  |q DE-84  |2 fid 
084 |a pha  |2 ssgn 
245 1 0 |a Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation  |b  = Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation 
246 3 1 |a Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation 
264 1 |a Bethesda (Maryland)  |b ClinicalTrials.gov  |c May 29, 2020 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Source: ClinicalTrials.gov (no modifications made) 
500 |a ClinicalTrials.gov processed this data on June 05, 2020 
500 |a Last update posted on ClinicalTrials.gov: May 29, 2020 
500 |a Last updated: 2020-06-08 
520 |a The current situation of Sars-Cov-2 pandemic generates fears in the general population. Among patients receiving long-term immunomodulatory drugs, especially in the context of auto-immune diseases, there may be legitimates interrogations about the appropriateness of continuing treatment, without modification, in the current context. Most patients with Juvenile Rheumatoid Arthritis benefit from long-term immunmodulatory therapy (DMARD - disease modifying anti-rheumatic drug), more or less combined with regular use of non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids.The present study will characterize this issue by defining the proportion of patients whose usual treatment of Rheumatoid Arthritis has been modified in relation to the actual sanitary crisis. 
650 4 |a Clinical Study Status: Recruiting 
650 4 |a Rheumatoid Arthritis 
650 4 |a COVID 
650 4 |a Clinical Study 
650 4 |a Klinische Studie 
650 4 |a Observational Study 
650 4 |a Arthritis  |x MeSH 
650 4 |a Arthritis, Rheumatoid  |x MeSH 
655 7 |a Forschungsbericht  |2 gnd-content 
710 2 |a University Hospital, Brest  |e Herausgebendes Organ  |4 isb 
856 4 0 |u https://clinicaltrials.gov/show/NCT04393233  |z Kostenfrei  |3 Volltext 
912 |a GBV_CTG 
936 u w |j 2020  |b 29  |c 05 
951 |a BO 
952 |j 2020  |b 29  |c 05